Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America

Ripeau Diego; Amartino Hernán; Cedrolla Martín; Urtiaga Luis; Urdaneta Bella; Cano Marilis; Valdez Rita; Antongiovanni Norberto; Masllorens Francisca

首页> 外文期刊>Medicina (Buenos Aires) >Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America

【24h】

Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America

机译：在拉丁美洲的Fabry病患者的酶替代治疗中，从阿糖苷酶β转换为阿糖苷酶α

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Medicina (Buenos Aires)》 |2017年第3期|共7页
作者
Ripeau Diego; Amartino Hernán; Cedrolla Martín; Urtiaga Luis; Urdaneta Bella; Cano Marilis; Valdez Rita; Antongiovanni Norberto; Masllorens Francisca;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa [J] . Hsiang-Yu Lin, Yu-Hsiu Huang, Hsuan-Chieh Liao, Journal of the Chinese Medical Association: JCMA . 2014,第4期

机译：法布里病患者进行酶替代治疗以及从阿糖苷酶β转换为阿糖苷酶α的临床观察
2. Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta [J] . Michael Beck, Christoph Kampmann Molecular genetics and metabolism . 2008,第1a2期

机译：法布里病中的酶替代疗法：α-半乳糖苷酶和β-半乳糖苷酶的比较
3. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al. [J] . Linthorst GE, Aerts JM Journal of inherited metabolic disease . 2011,第1期

机译：田中（Tanaka）等人关于“法布里氏病患者的酶替代疗法和抗阿糖苷酶β而不是抗阿糖苷酶α的IgE抗体的发展”的信。
4. Endothelial Targeted Enzyme Replacement Therapy for Fabry Disease [C] . D. Serrano, J. Hsu, K.V.N. Kumar, Annual meeting exposition of the Controlled Release Society . 2009

机译：Fabry病的内皮靶向酶替代治疗
5. Concurrent validity and responsiveness of the Peabody Developmental Motor Scales-2 in infants and children with Pompe disease undergoing enzyme replacement therapy [D] . Phillips, Dawn. 2012

机译：皮博迪发育运动量表2在接受酶替代疗法的庞贝病婴儿和儿童中的并发有效性和反应性
6. Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®) [O] . Kazuya Tsuboi, Hiroshi Yamamoto, Fuji Somura, 2015

机译：从严重的不良事件相关的法布里病患者中成功进行酶替代疗法的管理方法是从Agalsidase Beta（Fabrazyme®）转换为Agalsidase Alfa（Replagal®）
7. Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta (Fabrazyme®) to Agalsidase Alfa (Replagal®) [O] . Kazuya Tsuboi, Hiroshi Yamamoto, Fuji Somura, 2014

机译：通过从AgAlsidaseβ（Fabrazyme®）切换至AgAlsidase Alfa（Repagagal®），成功管理酶置换疗法患者严重不良事件的患者
8. Pilot Scale Isolation of Ceramide Trihexosidase from Human Plasma and Clinical Evaluation of Enzyme Replacement Therapy in Fabry's Disease. [R] . sweeley,charles c. 1975

机译：人体血浆中神经酰胺三己糖苷酶的中试分离及法布里氏病酶替代疗法的临床评价。

Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America

著录项

相似文献

相关主题

期刊订阅